Terms: = Prostate cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
2 results:
1. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved clinical outcome.
GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
[TBL] [Abstract] [Full Text] [Related]
2. cancer immunology--analysis of host and tumor factors for personalized medicine.
Ogino S; Galon J; Fuchs CS; Dranoff G
Nat Rev Clin Oncol; 2011 Aug; 8(12):711-9. PubMed ID: 21826083
[TBL] [Abstract] [Full Text] [Related]